The global cancer therapeutics market size accounted for USD 194.67 billion in 2024, grew to USD 212.58 billion in 2025 and is projected to surpass around USD 469.38 billion by 2034, representing a healthy CAGR of 9.20% between 2024 and 2034. The North America cancer therapeutics market size is calculated at USD 70.08 billion in 2024 and is expected to grow at a fastest CAGR of 9.35% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Therapeutics Market, by Top Selling Drugs Type, 2024-2034
8.1.1. Revlimid
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Avastin
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Herceptin
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Rituxan
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Opdivo
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Gleevec
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Velcade
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Imbruvica
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Ibrance
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Zytiga
8.1.10.1. Market Revenue and Forecast (2021-2034)
8.1.11. Alimta
8.1.11.1. Market Revenue and Forecast (2021-2034)
8.1.12. Xtandi
8.1.12.1. Market Revenue and Forecast (2021-2034)
8.1.13. Tarceva
8.1.13.1. Market Revenue and Forecast (2021-2034)
8.1.14. Perjeta
8.1.14.1. Market Revenue and Forecast (2021-2034)
8.1.15. Temodar
8.1.15.1. Market Revenue and Forecast (2021-2034)
8.1.16. Others
8.1.16.1. Market Revenue and Forecast (2021-2034)
9.1. Cancer Therapeutics Market, by Application, 2024-2034
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Cervical Cancer
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Head and Neck Cancer
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Glioblastoma
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Malignant Meningioma
9.1.9.1. Market Revenue and Forecast (2021-2034)
9.1.10. Mesothelioma
9.1.10.1. Market Revenue and Forecast (2021-2034)
9.1.11. Melanoma
9.1.11.1. Market Revenue and Forecast (2021-2034)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2021-2034)
10.1. Cancer Therapeutics Market, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Cancer and Radiation Therapy Centers
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Top Selling Drugs (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. F. Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AbbVie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AstellasPharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample